Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1974 1
1975 1
1977 2
1978 4
1979 2
1980 2
1981 1
1982 2
1983 5
1984 5
1985 2
1986 4
1987 4
1988 3
1989 7
1990 6
1991 5
1992 4
1994 4
1995 6
1996 1
1997 4
1998 3
1999 3
2000 2
2001 3
2002 6
2003 6
2004 3
2005 4
2006 5
2007 8
2008 8
2009 5
2010 5
2012 3
2013 10
2014 5
2015 5
2016 7
2017 4
2018 12
2019 11
2020 5
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

198 results
Results by year
Filters applied: . Clear all
Page 1
MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression.
Jiang Y, Zhang Y, Leung JY, Fan C, Popov KI, Su S, Qian J, Wang X, Holtzhausen A, Ubil E, Xiang Y, Davis I, Dokholyan NV, Wu G, Perou CM, Kim WY, Earp HS, Liu P. Jiang Y, et al. Among authors: earp hs. Nat Commun. 2019 Apr 3;10(1):1515. doi: 10.1038/s41467-019-09233-7. Nat Commun. 2019. PMID: 30944303 Free PMC article.
MerTK as a therapeutic target in glioblastoma.
Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR. Wu J, et al. Among authors: earp hs. Neuro Oncol. 2018 Jan 10;20(1):92-102. doi: 10.1093/neuonc/nox111. Neuro Oncol. 2018. PMID: 28605477 Free PMC article.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Carey LA, et al. Among authors: earp hs. JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492. JAMA. 2006. PMID: 16757721
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. Lee-Sherick AB, et al. Among authors: earp hs. JCI Insight. 2018 Nov 2;3(21):e97941. doi: 10.1172/jci.insight.97941. JCI Insight. 2018. PMID: 30385715 Free PMC article.
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Zawistowski JS, et al. Among authors: earp hs. Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20. Cancer Discov. 2017. PMID: 28108460 Free PMC article. Clinical Trial.
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL. Duncan JS, et al. Among authors: earp hs. Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053. Cell. 2012. PMID: 22500798 Free PMC article.
198 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page